论文部分内容阅读
目的 观察磷酸依托泊苷治疗小细胞肺癌的疗效及不良反应。方法 多中心随机临床研究 :A组磷酸依托泊苷 10 0 mg静脉滴注第 1～ 5天 ,加卡铂 30 0 mg/ m2第 1天 ,每 4周一次 ;B组 VP- 16 10 0 m g静脉滴注第 1～5天 ,加卡铂 30 0 m g/ m2第 1天 ,每 4周一次。 2～ 3周期后评定疗效 ,有效病例在 4周后确定疗效。结果 在可统计疗效的 6 4例中 ,A组 32例 ,CR5例 ,PR19例 ,有效 75 .0 %。B组 30例 ,CR1例 ,PR17例 ,有效率 6 0 .0 %。两组比较统计学无明显差异。不良反应主要是骨髓抑制、消化道反应及脱发 ,两组比较统计学亦无明显差异。结论 磷酸依托泊苷 (VP- 16的水溶性酯 )治疗小细胞肺癌和 VP- 16疗效、不良反应相似 ,其优点是可溶于水 ,制剂和给药均较 VP- 16更方便。
Objective To observe the efficacy and adverse reactions of etoposide phosphate in the treatment of small cell lung cancer. Methods Multi-center randomized clinical study: Group A Etoposide 100 mg intravenous drip for the first 1 to 5 days plus carboplatin 300 mg/m2 on the first day every 4 weeks; Group B VP-1610 0 mg Intravenous infusions for 1 to 5 days plus carboplatin 300 mg/m2 on the first day, every 4 weeks. After 2 to 3 cycles, the curative effect was evaluated. Effective cases were evaluated after 4 weeks. RESULTS Of the 64 patients with statistically effective results, 32 were in group A, 5 in CR, 19 in PR, effective 75.0 %. There were 30 patients in Group B, 1 in CR, 17 in PR, with an effective rate of 60.0%. There was no significant difference between the two groups in statistics. The adverse reactions were mainly myelosuppression, gastrointestinal reaction and hair loss. There was no significant difference between the two groups in statistics. Conclusion The efficacy and adverse reactions of etoposide phosphate (VP- 16 water-soluble ester) in the treatment of small cell lung cancer and VP-16 are similar. Its advantage is that it is soluble in water, and its preparation and administration are more convenient than VP-16.